Biocon Ltd

Biocon Ltd

Biocon Ltd has remitted the final dividend for the FY 2025-26, with a dividend of ₹ 0.50 per equity share.

Biocon Ltd

Biocon Ltd has received revised disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Mylan Inc. regarding the disposal of 9,19,67,019 shares of Biocon Ltd, representing 5.64% of the total share capital.

Biocon Ltd

Biocon Ltd announced marketing approval for its pegfilgrastim biosimilar from Japan's Ministry of Health, Labour and Welfare (MHLW). The product, a biosimilar to Neulasta, is developed and manufactured by Biocon Biologics Ltd, a wholly-owned subsidiary of Biocon Ltd.

Biocon Ltd

Biocon Ltd has received supplemental U.S. FDA approval for Yesintek® (ustekinumab-kfce) single-dose prefilled autoinjector, expanding its immunology portfolio in the United States.

Biocon Ltd

Biocon Ltd has scheduled a meeting with analysts/institutional investors as part of the Motilal Oswal 22nd Annual Global Investor Conference on August 17, 2026, in Mumbai. The meeting is subject to change due to exigencies. The company will not disclose any unpublished price-sensitive information during the meeting.

Biocon Ltd

Biocon Ltd has released the transcript of its Q1 FY27 earnings call, where the management team discussed the company's performance and future prospects, highlighting its strategic and financial strength, integration of biosimilars and generics businesses, and opportunities in the North American market.

Biocon Ltd

Biocon Ltd's 48th AGM was held through video conferencing, with voting results and Scrutinizer's report available on the company's website. The AGM approved the audited financial statements, declared a 10% final dividend, and appointed Eric Vivek Mazumdar as a director.

Biocon Ltd

Biocon Ltd has announced an investor meet with analysts and institutional investors on August 12, 2026, as part of Emkay Confluence 2026 Group Virtual. The company will not disclose any unpublished price sensitive information during the meeting.

Biocon Ltd

Biocon Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 43,360 million, profit before tax at Rs. 1,276 million, and profit attributable to shareholders at Rs. 1,411 million.

Biocon Ltd

Biocon Ltd has announced changes in its directorate and statutory auditors at its 48th Annual General Meeting (AGM). Mr. Eric Vivek Mazumdar has been re-appointed as a director, S.R. Batliboi & Associates LLP has been appointed as the new statutory auditors, and Mr. Nicholas Robert Haggar has retired as an independent director.

Biocon Ltd

Biocon Ltd has announced the completion of tenure of its Statutory Auditors, B S R & Co. LLP, and the appointment of S.R. Batliboi & Associates LLP as the new Statutory Auditors for a term of 5 years. Additionally, Mr. Eric Vivek Mazumdar has been re-appointed as Director liable to retire by rotation, and Mr. Nicholas Robert Haggar has retired as an Independent Director upon completion of his term.

Biocon Ltd

Biocon Ltd has announced the appointment of new statutory auditors, S.R. Batliboi & Associates LLP, and the re-appointment of Mr. Eric Vivek Mazumdar as a director. The changes were made at the 48th Annual General Meeting of the company.

Biocon Ltd

Biocon Ltd has announced changes in its directorate and statutory auditors at its 48th Annual General Meeting (AGM). Mr. Eric Vivek Mazumdar has been re-appointed as a director, S.R. Batliboi & Associates LLP has been appointed as the new statutory auditors, and Mr. Nicholas Robert Haggar has retired as an independent director.

Biocon Ltd

Biocon Ltd held its 48th Annual General Meeting (AGM) on August 06, 2026, through video conferencing, with 90 members present. The meeting was attended by the company's directors, key managerial personnel, and statutory auditors. The Chairperson, Ms. Kiran Mazumdar-Shaw, welcomed the attendees and informed about the non-attendance of certain directors due to personal exigencies. The meeting concluded with the appreciation of outgoing directors and auditors.

Biocon Ltd

Biocon Ltd has announced the availability of the audio and video recording of its Q1 FY27 earnings call, as per Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Biocon Ltd

Biocon Ltd has announced its Q1 FY27 earnings, with revenue from operations at ₹4,336 Cr, a 10% YoY growth. The company's biosimilars segment saw a 16% YoY growth, driven by the North America market, while the generics segment reported a 21% YoY growth. The company's EBITDA margin for the biosimilars segment was 25%, and 7% for the generics segment.

Biocon Ltd

Biocon Ltd has received a Monitoring Agency Report from India Ratings & Research Private Limited for the quarter ended June 30, 2026, regarding the utilization of proceeds raised through Qualified Institutions Placement. The report states that there is no deviation from the objects of the issue.

Biocon Ltd

Biocon Ltd announced its consolidated financial results for Q1FY27, with total income at Rs 4,391 Cr, up 9% YoY, driven by strong growth in the Biopharma business. Biopharma revenue grew 17% YoY, driven by momentum from recent biosimilar and generic product launches across key markets.

Biocon Ltd

Biocon Ltd announced its unaudited financial results for the quarter ended June 30, 2026, with a net profit of Rs. 638 million and a basic earnings per share of Rs. 0.32. The company's consolidated financial results also showed a net profit of Rs. 1,368 million. The results will be available on the company's website.

Biocon Ltd

Biocon Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, showing a net profit of Rs. 522 million. The company's revenue from operations was Rs. 6,245 million, and its expenses were Rs. 6,194 million. The results are available on the company's website.